Guizhou Yibai Pharmaceutical Co., Ltd. (SHA:600594)

China · Delayed Price · Currency is CNY

3.880

+0.050 (1.31%)

Aug 20, 2026, 3:00 PM CST

SHA:600594 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,559	1,863	2,174	2,821	2,735	3,347
Revenue Growth	-22.00%	-14.31%	-22.92%	3.12%	-18.27%	-1.95%
Gross Profit	896.13	1,083	1,322	1,885	1,921	2,599
Operating Income	-165.37	-148.68	-258.95	143.79	249.46	433.12
Net Income	-390	-329.56	-317.22	103.4	-426.39	243.77
Earnings Per Share	-0.50	-0.42	-0.40	0.13	-0.54	0.31
EPS Growth	-	-	-	-	-	6.57%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Pharmaceutical Industry	1,446
Medical Services	400.55
Total	1,847

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	430.23	467.2	541.01	699.47	592.36	379.63
Total Debt	688.43	684.31	948.01	992.65	1,087	912.11
Net Cash (Debt)	-258.2	-217.11	-407	-293.18	-494.6	-532.48
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.33	-0.28	-0.52	-0.37	-0.62	-0.67

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	150.29	256.71	86.87	377.61	345.3	934.21
Capital Expenditures	-34.84	-34.99	-96.32	-130.38	-322.92	-447.78
Free Cash Flow	115.46	221.71	-9.45	247.23	22.38	486.43
Free Cash Flow Growth	-	-	-	1004.93%	-95.40%	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	57.47%	58.15%	60.81%	66.82%	70.22%	77.65%
Operating Margin	-10.61%	-7.98%	-11.91%	5.10%	9.12%	12.94%
Pretax Margin	-23.15%	-16.73%	-15.30%	4.69%	-14.33%	9.27%
Profit Margin	-25.01%	-17.69%	-14.59%	3.67%	-15.59%	7.28%
FCF Margin	7.41%	11.90%	-0.43%	8.77%	0.82%	14.54%

Dividends

Fiscal Year	FY 2023
Period Ending	Dec '23 Dec 31, 2023
Dividend Per Share	0.066
Dividend Per Share Growth	-
Dividend Yield	1.19%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 21, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	-	43.58	-	26.41
Forward PE	-	19.12	19.12	19.12	19.12	19.12
P/FCF Ratio	26.36	14.08	-	18.23	195.73	13.24
PS Ratio	1.95	1.68	1.29	1.60	1.60	1.92